Soleus Capital Maintains 10.0% Stake in Mereo BioPharma

TL;DR

**Soleus Capital still owns 10% of Mereo BioPharma, showing continued confidence.**

AI Summary

Soleus Private Equity Fund III, L.P. and its affiliates, including Soleus Capital Group, LLC, filed an amended Schedule 13G/A on February 6, 2024, updating their ownership in Mereo BioPharma Group plc. As of December 31, 2023, the Soleus entities collectively reported beneficial ownership of 11,850,000 Ordinary Shares, representing 10.0% of the company's outstanding shares. This matters to investors because Soleus Capital is a significant institutional holder, and their continued substantial stake indicates a strong belief in Mereo's future, potentially signaling stability or future strategic involvement.

Why It Matters

A major institutional investor like Soleus Capital holding a 10.0% stake can influence company decisions and signals confidence in Mereo BioPharma's long-term prospects, which could be a positive indicator for other investors.

Risk Assessment

Risk Level: low — This filing indicates a stable, significant institutional ownership, which generally reduces volatility and provides a level of oversight.

Analyst Insight

Investors should note the continued significant institutional ownership by Soleus Capital, which suggests a stable long-term investment perspective. This could be a positive signal, but further research into Mereo's fundamentals and Soleus's investment thesis would be prudent.

Key Numbers

• 11,850,000 — Ordinary Shares (Total shares beneficially owned by Soleus Capital Group as of December 31, 2023.)
• 10.0% — Ownership Percentage (Percentage of Mereo BioPharma Group plc's Ordinary Shares beneficially owned by Soleus Capital Group.)
• December 31, 2023 — Reporting Date (The date as of which the ownership stake was reported in the filing.)

Key Players & Entities

• Soleus Private Equity Fund III, L.P. (company) — reporting person and beneficial owner
• Mereo BioPharma Group plc (company) — subject company
• Soleus Capital Group, LLC (company) — group member and beneficial owner
• GUY LEVY (person) — group member
• 11,850,000 (dollar_amount) — number of Ordinary Shares beneficially owned

Forward-Looking Statements

• Soleus Capital Group will maintain a significant ownership stake in Mereo BioPharma Group plc. (Soleus Capital Group) — high confidence, target: Next 12 months
• Mereo BioPharma Group plc will continue its operations in pharmaceutical preparations. (Mereo BioPharma Group plc) — high confidence, target: Next 24 months

FAQ

Filing Documents

• ea192957-13ga1soleus3_mereo.htm (SC 13G/A) — 156KB
• 0001213900-24-010559.txt ( ) — 158KB

From the Filing

SC 13G/A 1 ea192957-13ga1soleus3_mereo.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* MEREO BIOPHARMA GROUP PLC (Name of Is suer) Ordinary Shares, £0.003 par value (Title of Class of Securities) 589492107** (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise ** There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 589492107 has been assigned to the American Depositary Receipts (“ ADRs ”) of the Issuer, which are quoted on the Nasdaq Global Market under the symbol “MREO.” Each ADR represents 5 Ordinary Shares. CUSIP NO. 589492107 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Soleus Private Equity Fund III, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 18,145,160 ordinary shares represented by 3,629,032 ADRs (1) 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 18,145,160 ordinary shares represented by 3,629,032 ADRs (1) 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 18,145,160 ordinary shares represented by 3,629,032 ADRs (1) 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.6% (2) 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN FOOTNOTES (1) The shares are owned directly by Soleus Private Equity Fund III, L.P. (“Soleus PE”). Soleus Private Equity GP III, LLC (“Soleus GP”) is the sole general partner of Soleus PE. Soleus GP holds voting and dispositive power over the shares held by Soleus PE. Soleus PE GP III, LLC is the sole manager of Soleus GP. Mr. Guy Levy is the sole managing member of Soleus PE GP III, LLC. Each of Mr. Guy Levy, Soleus PE GP III, LLC and Soleus GP disclaims beneficial ownership of these securities held by Soleus PE and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or for any other purpose, except to the extent of their respective pecuniary interests therein. (2) This percentage is calculated based upon 701,217,089 ordinary shares outstanding of Mereo BioPharma Group plc (the “Issuer”) as of August 31, 2023, as set forth on the Issuer’s website. 2 CUSIP NO. 589492107 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Soleus Private Equity GP III, LLC 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 18,145,160 ordinary shares represented by 3,629,032 ADRs (1) 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 18,145,160 ordinary shares represented by 3,629,032 ADRs (1) 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 18,145,160 ordinary shares represented by 3,629,032 ADRs (1) 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.6% (2) 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO FOOTNOTES (1) The ordinary shares reported in this row are owned directly by Soleus PE. Soleus GP is the sole general partner of Soleus PE. Soleus GP holds voting and dispositive power over the shares held by Soleus PE. Soleus PE GP III, LLC is the sole manager of Soleus GP. Mr. Guy Levy is the sole managing member of Soleus PE GP III, LLC. (2) This percentage is calculated based upon 701,217,089 ordinary shares outstanding of the Issuer as of August 31, 2023. 3 CUSIP NO. 589492107 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Soleus PE GP III, LLC 2 CHECK THE APPR

View Full Filing

View this SC 13G/A filing on SEC EDGAR